Blueprint Investment Partners’s Vertex Pharmaceuticals VRTX Stock Holding History

Blueprint Investment Partners’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-633	Closed	-$220K	–	151
2023 Q3	$220K	Sell	633 -221	-26%	-$77.3K	0.07%	102
2023 Q2	$301K	Buy	+854	New	+$288K	0.11%	119
2022 Q4	–	Sell	-910	Closed	-$263K	–	257
2022 Q3	$263K	Sell	910 -131	-13%	-$37.7K	0.07%	112
2022 Q2	$293K	Buy	1,041 +81	+8%	+$21.7K	0.08%	113
2022 Q1	$251K	Buy	960 +286	+42%	+$67.9K	0.06%	145
2021 Q4	$148K	Buy	+674	New	+$131K	0.04%	211

Other funds holding VRTX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Blueprint Investment Partners's VRTX Position: Q4 2023 in Review

Blueprint Investment Partners sold out of Vertex Pharmaceuticals (VRTX) in Q4 2023, closing a stake of 633 shares — an estimated $220K sold.

Blueprint Investment Partners first reported a position in VRTX in Q4 2021 and held it in 6 quarters. The position peaked at $301K in Q2 2023. 1,439 funds tracked by Wall St. Rank hold VRTX as of Q4 2023.

Blueprint Investment Partners reported no remaining Vertex Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Blueprint Investment Partners sold 633 Vertex Pharmaceuticals shares in Q4 2023, an estimated $220K.
Blueprint Investment Partners first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 6 quarters.
Blueprint Investment Partners's Vertex Pharmaceuticals position peaked at $301K in Q2 2023.
1,439 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2023.

Based on Blueprint Investment Partners's 13F filing for Q4 2023, filed 13 Feb 2024.